Cargando…
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/ https://www.ncbi.nlm.nih.gov/pubmed/32344789 http://dx.doi.org/10.3390/jcm9041241 |
_version_ | 1783535078964461568 |
---|---|
author | Quint, Tamara Brunner, Patrick M. Sinz, Christoph Steiner, Irene Ristl, Robin Vigl, Kornelia Kimeswenger, Susanne Neubauer, Katharina Pirkhammer, Detlev Zikeli, Martin Hoetzenecker, Wolfram Reider, Norbert Bangert, Christine |
author_facet | Quint, Tamara Brunner, Patrick M. Sinz, Christoph Steiner, Irene Ristl, Robin Vigl, Kornelia Kimeswenger, Susanne Neubauer, Katharina Pirkhammer, Detlev Zikeli, Martin Hoetzenecker, Wolfram Reider, Norbert Bangert, Christine |
author_sort | Quint, Tamara |
collection | PubMed |
description | Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. |
format | Online Article Text |
id | pubmed-7230957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72309572020-05-22 Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis Quint, Tamara Brunner, Patrick M. Sinz, Christoph Steiner, Irene Ristl, Robin Vigl, Kornelia Kimeswenger, Susanne Neubauer, Katharina Pirkhammer, Detlev Zikeli, Martin Hoetzenecker, Wolfram Reider, Norbert Bangert, Christine J Clin Med Article Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. MDPI 2020-04-24 /pmc/articles/PMC7230957/ /pubmed/32344789 http://dx.doi.org/10.3390/jcm9041241 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Quint, Tamara Brunner, Patrick M. Sinz, Christoph Steiner, Irene Ristl, Robin Vigl, Kornelia Kimeswenger, Susanne Neubauer, Katharina Pirkhammer, Detlev Zikeli, Martin Hoetzenecker, Wolfram Reider, Norbert Bangert, Christine Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_full | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_fullStr | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_full_unstemmed | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_short | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_sort | dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/ https://www.ncbi.nlm.nih.gov/pubmed/32344789 http://dx.doi.org/10.3390/jcm9041241 |
work_keys_str_mv | AT quinttamara dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT brunnerpatrickm dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT sinzchristoph dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT steinerirene dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT ristlrobin dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT viglkornelia dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT kimeswengersusanne dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT neubauerkatharina dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT pirkhammerdetlev dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT zikelimartin dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT hoetzeneckerwolfram dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT reidernorbert dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT bangertchristine dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis |